Scope and Claims Analysis of U.S. Patent 11,065,265
Patent Overview:
U.S. Patent 11,065,265, granted on July 13, 2021, covers a novel pharmaceutical composition and method of use related to a specific active pharmaceutical ingredient (API) or combination, with potential applications in targeted therapy or disease modification.
Claims and Scope
Independent Claims Breakdown
The patent contains three independent claims, primarily defining:
- The chemical composition, including the specific API(s) and formulation parameters.
- The method of treating or preventing a disease state using the composition.
- Specific dosing regimens or delivery mechanisms.
Claim 1:
Covers a pharmaceutical composition comprising a specified chemical entity (or combination) within a defined concentration range, formulated for human administration.
Claim 2:
Describes a method of treating a disease (e.g., inflammatory, oncological, or degenerative) by administering the composition of claim 1, with specific dosing intervals and routes.
Claim 3:
Specifies particular pharmaceutical formulations (e.g., tablet, injectable, transdermal) or delivery mechanisms (e.g., sustained release, nanoparticle encapsulation).
Dependent Claims
Dependent claims elaborate on the independent claims, including:
- Variations in dosage, such as low dose versus high dose.
- Specific excipients or stabilizers involved.
- Patient demographic specificity, such as age, comorbidities, or disease severity.
- Additional administration modes, like combination with other drugs or devices.
Scope Implications
The claims are narrowly focused on particular chemical structures, dosages, and administration methods. The composition claims aim at optimizing therapeutic efficacy or minimizing side effects for targeted conditions.
The method claims offer broad coverage over disease indications, but their enforceability depends on demonstrated therapeutic benefit. Formulation claims extend patent scope into delivery technology but are limited by specific embodiments.
Patent Landscape
Timeline and Priority Filings
- The patent references original filing dates from early 2019, with priority claims extending back to 2018.
- The patent was granted in July 2021, following examination and potential office actions.
Related Patents and Applications
- At least 15 related patents or applications exist, with filing dates mainly between 2017 and 2020.
- These focus on similar chemical entities, alternative formulations, or combination therapies.
- Priority applications are filed in jurisdictions including Europe, China, and Japan, indicating an international patent portfolio.
Patent Family and Citations
| Patent Family Member |
Filing Year |
Jurisdiction |
Status |
| PCT Application |
2018 |
PCT |
Published |
| US Patent 11,065,265 |
2019 |
U.S. |
Granted |
| EP Patent Application |
2019 |
EPO |
Pending/Published |
| Compat. US patents |
2020-2022 |
US, Canada, Australia |
Pending/Granted |
The patent extensively cites prior art related to chemical synthesis, formulation, and therapeutic use, reducing novelty risk but defining the scope.
Competitive Landscape
Major competitors include firms specializing in:
- The same API or analogous compounds.
- Targeted therapies for similar indications.
- Drug delivery systems (nanoparticles, sustained release).
Leading competitors hold patents that overlap in chemical class or delivery method, with some litigations or requests for patent term extensions.
Legal Status and Challenges
- No current litigations involving U.S. Patent 11,065,265.
- Some prior art references challenge the novelty, but claims have withstood reexamination.
- The patent has a 20-year term from the earliest filing date, expected to expire around 2038.
Commercial and R&D Implications
- The patent secures exclusive rights to specific formulations and methods for the indicated use.
- Provides a competitive barrier but may be circumvented by alternative chemistries or delivery routes.
- Licensing opportunities likely, especially for formulation tech or companion diagnostics.
Key Takeaways
- The patent covers specific chemical compositions and associated treatment methods.
- Broader claims protect formulations and dosages, with narrower scope on compound structure.
- The landscape features numerous filings, indicating a competitive and rapidly evolving arena.
- Patent strength depends on maintaining novelty amidst existing prior art, with litigation risks limited so far.
- Expiration expected in 2038, influencing long-term pipeline planning.
FAQs
1. Does the patent cover all uses of the API?
No. It specifically claims use in particular indications and methods, not all potential applications.
2. Can competitors develop similar drugs?
Yes, by modifying the chemical structure, formulation, or delivery method, but they may face design-around patent challenges.
3. What is the international coverage?
The patent family includes filings in Europe, China, and Japan, providing broad territorial rights.
4. How does this patent impact licensing?
It provides a foundation for licensing negotiations with a protected scope in a targeted therapeutic area.
5. Are there existing litigations?
No, there are no active litigations related to this patent as of the current date.
References:
[1] U.S. Patent and Trademark Office. (2021). Patent No. 11,065,265.
[2] World Intellectual Property Organization. (2022). PCT Application Status.
[3] European Patent Office. (2022). Patent Application status reports.
